Biotia, the clinical metagenomics company whose BIOTIA-ID Urine Test identifies the cause of recurrent and complicated urinary tract infections (UTIs) with 97% sensitivity and 99% specificity, today announced an oversubscribed $9 million financing. The test is available to physicians and patients in all 50 states.

Tim Barry and Clive Fields, MD, cofounders of VillageMD, joined other investors in this funding, including Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels, Red Bear Ventures, and others.

Biotia is advancing infectious disease diagnostics for challenging and chronic infections through pathogen genomics and artificial intelligence. As a spinout company of the Jacobs Technion-Cornell Institute at Cornell Tech, Biotia is based in New York City, where it operates a high-complexity, CLIA-certified diagnostic laboratory. Biotia's partners and collaborators include leading institutions such as Mayo Clinic, Hospital for Special Surgery (HSS), and NASA. Biotia develops cutting-edge diagnostic and software solutions to help patients, providers, and health systems identify and respond to infectious disease threats. Its flagship diagnostic test for recurrent, complicated UTIs, the BIOTIA-ID Urine Test (sensitivity 97% and specificity 99%), is available across all 50 U.S. states.